1 Shin J,Hunt CM,Suzuki A,et al.Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. Pharmacoepidemiol Drug Saf,2013,22:190-198. 2 Chen M,Zhang J,Wang Y,et al.The liver toxicity knowledge base:a systems approach to a complex end point. Clin Pharmacol Ther,2013,93:409-412. 3 Bell LN,Chalasani N.Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis,2009,29:337-347. 4 Danan G,Benichou C.Causality assessment of adverse reactions to drugs--I. Anovel method based on the conclusions ofinternational consensus meetings:application to drug-induced liver injuries. JClin Epidemiol,1993,46:1323-1330. 5 Devarbhavi H,Karanth D,Prasanna KS,et al.Drug-induced liver injury with hypersensitivity features has a better outcome:a single-center experience of 39 children and adolescents. Hepatology,2011,54:1344-1350. 6 Roth RA,Ganey PE.Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one.JPharmacol Exp Ther,2010,332:692-697. 7 Larson AM,Polson J,Fontana RJ,et al.Aceta minophen-induced acute liver failure:results of a United States Multicenter,prospective study. Hepatology,2005,42:1364-1372. 8 Gulmez SE,Larrey D,Pageaux GP,et al.Transplantation for acute liver failure in patients exposed to NSAIDs or paraceta Mol (aceta minophen):the Multinational case-population SALTstudy. Drug Saf,2013,36:135-144. 9 Ekor M.The growing use of herbal medicines:issues relating to adverse reactions and challenges in Monitoring safety. Front Pharmacol,2014,4:177. 10 Andrade RJ,Lucena MI,Alonso A,et al.HLAclass IIgenotype influences the type ofliverinjury in drug-induced idiosyncratic liver disease. Hepatology,2004,39:1603-1612. 11 Bjornsson E.Drug-induced liver injury:Hy's rule revisited. Clin Pharmacol Ther,2006,79:521-528. 12 Chalasani N,Fontana RJ,Bonkovsky HL,et al.Causes,clinical features,and outcomes fro Ma prospective study of drug-induced liver injury in the United States. Gastroenterology,2008,135:1924-1934. |